{
  "docId": "019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "docSlug": "7d5a5b546ee496a809a6ede1a6c2c260",
  "documentTitle": "Equillium | Investor Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 32,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a simple list-based timeline format.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7b67-762e-8b55-8f35aa9a2cc0/31",
  "deckHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "deckJsonHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0.json",
  "deckAnchorHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 1,
        "x": 0,
        "y": 0.66
      },
      "kind": "callout",
      "text": "Cash runway expected to extend into 2025*. Potential Ono Exercise Payment of ~$33M** would significantly extend cash runway",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2688b81-2554-4692-8ecc-4f84384fe62d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.165,
        "w": 0.926,
        "x": 0.037,
        "y": 0.413
      },
      "kind": "list",
      "text": "Itolizumab – Phase 1b / Phase 3 Clinical Studies: Lupus Nephritis EQUALISE Study (Phase 1b) – Topline Data (Early 2024); aGVHD EQUATOR Study (Phase 3) – Interim Review (2024)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "146261e2-0697-44a5-8d8e-399ef92bffdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.105,
        "w": 0.926,
        "x": 0.037,
        "y": 0.278
      },
      "kind": "list",
      "text": "EQ101 – Phase 2 Clinical Study: Alopecia Areata – Topline Data (Q2 2024)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30c5055a-a59a-43cc-834b-03a07b89c923",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.734,
        "x": 0.163,
        "y": 0.965
      },
      "kind": "source-note",
      "text": "* Estimated based on current operating plan ** Option exercise payment of ¥5.0B is based in JPY and subject to currency exchange rate at the time of payment",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a469ce54-28db-4f5e-86c1-7ed6080abfe0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.179,
        "x": 0.037,
        "y": 0.075
      },
      "kind": "title",
      "text": "Milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6037f8c-721c-46d2-8bc4-373ef14254f3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "8dd14ade-69aa-4dcc-a5b5-ce68e0d03ee0",
      "evidence": "The slide presents a sequence of future clinical milestones mapped to specific timeframes.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}